Rett Syndrome| A Pipeline Analysis Report 2018| Technavio
23 Juli 2018 - 07:18PM
Business Wire
Technavio has announced their latest pipeline analysis report on
the Rett syndrome market. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period to treat Rett syndrome.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180723005606/en/
Technavio has published a new report on
the drug development pipeline for Rett syndrome, including a
detailed study of the pipeline molecules. (Graphic: Business
Wire)
This report by Technavio presents a detailed analysis of
the market, including regulatory framework, drug development
strategies, recruitment strategies, and key companies that are
expected to play an essential role in the growth of the market in
the future.
This report is available at a USD 1,000 discount for a
limited time only: View market snapshot before
purchasing
Rett syndrome: Market
overview
Rett syndrome is one of the rare genetic neurological disorders.
It majorly affects the development of the brain and further leads
to the inability of a person to use muscles for body movements and
speech. It can also result in seizures and intellectual
disability.
According to a senior market research analyst
at Technavio, “Long-time complications of Rett syndrome can result
in difficulty in eating, constipation, unusual sleep patterns, and
muscle and joint problems. As a result, with increasing incidences
of the syndrome, the need for drug development for Rett syndrome is
expected to increase considerably in the next few years.”
Rett syndrome: Segmentation
analysis
This pipeline analysis report segments the Rett syndrome market
based on therapies employed (monotherapy), RoA (oral, subcutaneous,
and intrathecal), therapeutic modality (small molecule, gene
therapy and protein), targets (CDKLS protein, glutamate, microglia,
NMDA receptor, mitochondrial protein, serotonin,
sphingosine-1-phosphate receptor, and LSD1), MoA (NMDA receptor
agonist, mitochondrial protein modulator, serotonin receptor,
sphingosine-1-phosphate receptor stimulator, CDKLS protein
replacement, glutamate modulator, and LSD1 inhibitor), geographical
segmentation (US, Switzerland, Australia, India, Italy, and UK) and
recruitment status (active, not recruiting, completed, and
recruiting). It provides an in-depth analysis of the prominent
factors influencing the market, including drivers, opportunities,
trends, and industry-specific challenges.
Based on therapeutic modality, about 61% of the molecules that
are being investigated for the treatment of Rett syndrome are small
molecule.
Looking for more information on this market? Request a
free sample report
Technavio’s sample reports are free of charge and contain
multiple sections of the report such as the market size and
forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and
advisory company. Their research and analysis focuses on emerging
market trends and provides actionable insights to help businesses
identify market opportunities and develop effective strategies to
optimize their market positions.
With over 500 specialized analysts, Technavio’s report library
consists of more than 10,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio’s comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
If you are interested in more information, please contact our
media team at media@technavio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180723005606/en/
Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS:
+1 844 364 1100UK: +44 203 893 3200www.technavio.com